Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Klebanoff

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Cancer Immunology Research|June 29, 2022
T-cell Receptor Gene Therapy Clinically Targeting a TP53 Public NeoantigenChristopher A Klebanoff
Blood|September 22, 2012
Stubborn Tregs limit T-cell therapyChristopher A Klebanoff, Luca Gattinoni
Immunity|March 10, 2021
Erasing iatrogenic neoantigens from in vivo CRISPR screensFei Yi, Christopher A Klebanoff
Cancer Cell|December 13, 2022
Less, but better: A simplified design for T cell redirection and conditional payload deliveryKorbinian N Kropp, Christopher A Klebanoff
Immunological Reviews|July 30, 2019
T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistanceSmita S Chandran, Christopher A Klebanoff
The Journal of Experimental Medicine|December 23, 2017
Shared cancer neoantigens: Making private matters publicChristopher A Klebanoff, Jedd D Wolchok
Cell|October 8, 2016
Customizing Functionality and Payload Delivery for Receptor-Engineered T CellsChristopher A Klebanoff, Nicholas P Restifo
Science Translational Medicine|April 8, 2010
Pharmacologic induction of CD8+ T cell memory: better living through chemistryLuca Gattinoni, Christopher A Klebanoff, Nicholas P Restifo
Nature Reviews. Cancer|September 22, 2012
Paths to stemness: building the ultimate antitumour T cellLuca Gattinoni, Christopher A Klebanoff, Nicholas P Restifo
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Christopher A Klebanoff, Luca Gattinoni, Nicholas P Restifo
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Cancer Immunology Research|June 29, 2022
T-cell Receptor Gene Therapy Clinically Targeting a TP53 Public NeoantigenChristopher A Klebanoff
Blood|September 22, 2012
Stubborn Tregs limit T-cell therapyChristopher A Klebanoff, Luca Gattinoni
Immunity|March 10, 2021
Erasing iatrogenic neoantigens from in vivo CRISPR screensFei Yi, Christopher A Klebanoff
Cancer Cell|December 13, 2022
Less, but better: A simplified design for T cell redirection and conditional payload deliveryKorbinian N Kropp, Christopher A Klebanoff
Immunological Reviews|July 30, 2019
T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistanceSmita S Chandran, Christopher A Klebanoff
The Journal of Experimental Medicine|December 23, 2017
Shared cancer neoantigens: Making private matters publicChristopher A Klebanoff, Jedd D Wolchok
Cell|October 8, 2016
Customizing Functionality and Payload Delivery for Receptor-Engineered T CellsChristopher A Klebanoff, Nicholas P Restifo
Science Translational Medicine|April 8, 2010
Pharmacologic induction of CD8+ T cell memory: better living through chemistryLuca Gattinoni, Christopher A Klebanoff, Nicholas P Restifo
Nature Reviews. Cancer|September 22, 2012
Paths to stemness: building the ultimate antitumour T cellLuca Gattinoni, Christopher A Klebanoff, Nicholas P Restifo
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Christopher A Klebanoff, Luca Gattinoni, Nicholas P Restifo
Pageof 11